On July 14, 2025, Keybanc analyst Aleksey Yefremov announced the maintenance of the "Overweight" rating for Phreesia (PHR, Financial), a healthcare technology company listed on the New York Stock Exchange.
The analyst also raised the target price for Phreesia (PHR, Financial) from $28.00 to $35.00, which represents a 25% increase. This adjustment in the target price reflects a positive outlook on the company's projected performance.
The current rating of "Overweight" remains unchanged as per Keybanc's latest assessment, continuing the previous rating stance on Phreesia (PHR, Financial). The currency for the target price is in USD.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Phreesia Inc (PHR, Financial) is $32.15 with a high estimate of $35.00 and a low estimate of $29.00. The average target implies an upside of 20.34% from the current price of $26.72. More detailed estimate data can be found on the Phreesia Inc (PHR) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Phreesia Inc's (PHR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Phreesia Inc (PHR, Financial) in one year is $32.84, suggesting a upside of 22.9% from the current price of $26.72. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Phreesia Inc (PHR) Summary page.
